Eli Lilly and J&J Rally on Fresh Data While Software Stocks Slide
Pharma giants Eli Lilly and J&J caught a bid on new data, but software stocks are handing back last week's hard-won gains.
Two of the biggest names in pharma are flashing green today. Eli Lilly and Johnson & Johnson both bounced after fresh data hit the tape, giving traders a reason to rotate back into healthcare ahead of the close. When new clinical or product data drops mid-session, the market tends to react fast — and today was no exception.
Meanwhile, software is getting punished. The sector gave up the gains it spent all of last week building, which tells you sentiment in high-multiple tech names is still fragile. One strong week doesn't erase the macro overhang, and sellers are proving that point right now.
Read more Hedge Fund Had 76% in Five AI Stocks Before Major Selloff →
This kind of rotation — out of momentum software and into data-driven pharma — is exactly the type of move you want to track in the final hour. The last 60 minutes of trading can exaggerate these swings, especially when institutional desks are rebalancing into the close.
If you're positioned in software longs, today's price action is a warning shot. It doesn't mean the trade is dead, but it does mean you should know where your stops are. On the flip side, the pharma bounce could have legs if the underlying data holds up under scrutiny.
The CNBC Investing Club's Homestretch flagged this setup in its afternoon update, giving members an actionable look at the market dynamic heading into the final hour. Continue reading at US Top News and Analysis.
